Home 2018-04-24T12:41:05+00:00
What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies

– A CD19 CAR with novel targeting properties designed to reduce cytokine release syndrome –

Autolus Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the execution of a license agreement under which Autolus has acquired global rights from UCL Business plc (UCLB), the technology-transfer company of University College London (UCL), to develop and commercialize a novel CD19 chimeric antigen receptor (CAR) T cell therapy with novel targeting properties for the treatment of B cell malignancies.

Read More
Featured Technology—

Novel method of analysis of stroke data

Stroke is the leading cause of adult disability in the UK at an estimated cost of £7 billion a year. UCL has developed a system for predicting clinical outcomes so as to provide advance information on the optimum clinical management of each patient.
Read more
Spotlight—

Children are not small adults.

When it comes to the use of medicines, children cannot be treated as small adults.  Find out how our spinout, Therakind, is ensuring that children’s medicine used today is both safe and effective.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

Autolus features in Fierce Biotech

/ UCLB News
UCLB spinout, Autolus, features in a recent Fierce Biotech article, after filing to raise $100 million in a Nasdaq IPO ...

UCL Technology Fund and UK Innovation & Science Seed Fund invest in cell therapy company Glialign

/ Spinout News
The UCL Technology Fund (UCLTF), UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in ...

UCLB Spin out Hazy, wins Microsoft Innovate AI competition

/ Spinout News
Hazy (formerly Anon AI), one of our spin out companies, has won this year’s Microsoft Innovate AI competition. The award ...

UCLB spinout Endomag receives The Queen’s Award for its innovation in breast cancer treatment

/ UCLB News
Endomag, the surgical guidance company, announced it has received the Queen’s Award for Enterprise in Innovation for 2018. The Award ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Bringing innovation to life

0
Active spinouts
0
Active licences in 2016
0
Drug discoveries
0
New patent applications